Brought to you by 
Orexigen grants Valeant license to sell Contrave in Australia, New Zealand
08 Nov 2016
Executive Summary
Orexigen Therapeutics Inc. licensed Valeant Pharmaceuticals International Inc. rights to commercialize its obesity therapy Contrave (naltrexone HCl/bupropion HCl extended release) in Australia and New Zealand.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Orexigen grants Valeant license to sell Contrave in Australia, New Zealand
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice